SUPPLEMENT

Q4 2021 — Financial disclosures

Q4 2021PDF · 10 pages1.1 MB
Merck & Co., Inc.
Financial Highlights Package
Fourth Quarter 2021
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 4Q21 and Dec YTD 21........3
Table 2b: GAAP to Non-GAAP Reconciliation 4Q20 and Dec YTD 20........4
Table 3: Sales - Current Year and Prior Year by Quarter..........................5
Table 3a: Sales – U.S. / Ex- U.S. 4Q21.......................................................6
Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 21 ............................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense..............................................................9

-- 1 of 10 --

Sales 	13,521	$ 	10,948	$ 	24% 	48,704	$ 	41,518	$ 	17%
Costs, Expenses and Other
Cost of sales 	3,873 	5,029 	-23% 	13,626 	13,618 	0%
Selling, general and administrative 	2,830 	2,619 	8% 	9,634 	8,955 	8%
Research and development 	3,068 	5,788 	-47% 	12,245 	13,397 	-9%
Restructuring costs (1) 174 	310 	-44% 	661 	575 	15%
Other (income) expense, net 	(333) 	(253) 	32% 	(1,341) 	(890) 	51%
Income (Loss) from Continuing Operations Before Taxes 	3,909 	(2,545) 	* 	13,879 	5,863 	*
Income Tax Provision 	85 	69 	1,521 	1,340
Net Income (Loss) from Continuing Operations 	3,824 	(2,614) 	* 	12,358 	4,523 	*
Less: Net Income Attributable to Noncontrolling Interests 	4 	3 	13 	4
Net Income (Loss) from Continuing Operations Attributable to Merck
& Co., Inc. 3,820	$ 	(2,617)	$ 	* 	12,345	$ 	4,519	$ 	*
(Loss) Income from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests (62)	$ 	523	$ 	* 	704	$ 	2,548	$ 	-72%
Net Income (Loss) Attributable to Merck & Co., Inc. 	3,758	$ 	(2,094)	$ 	* 	13,049	$ 	7,067	$ 	85%
Basic Earnings (Loss) per Common Share Attributable to Merck &
Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.51	$ 	(1.03)	$ 	* 	4.88	$ 	1.79	$ 	*
(Loss) Income from Discontinued Operations 	(0.02)	$ 	0.21	$ 	* 	0.28	$ 	1.01	$ 	-72%
Net Income (Loss) 	1.49	$ 	(0.83)	$ 	* 	5.16	$ 	2.79	$ 	85%
Earnings (Loss) per Common Share Assuming Dilution Attributable to
Merck & Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.51	$ 	(1.03)	$ 	* 	4.86	$ 	1.78	$ 	*
(Loss) Income from Discontinued Operations 	(0.02)	$ 	0.21	$ 	* 	0.28	$ 	1.00	$ 	-72%
Net Income (Loss) 	1.48	$ 	(0.83)	$ 	* 	5.14	$ 	2.78	$ 	85%
Average Shares Outstanding 	2,527 	2,530 	2,530 	2,530
Average Shares Outstanding Assuming Dilution (2) 2,535 	2,530 	2,538 	2,541
Tax Rate from Continuing Operations 	2.2% 	-2.7% 	11.0% 	22.9%
* 100% or greater
(1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.
(2) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming
dilution as the effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding.
GAAP
% Change
GAAP
% Change
4Q21 	4Q20 Full Year
2021
Full Year
2020
On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to company
shareholders. The historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off
are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided
below.
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
1

-- 2 of 10 --

Sales 	10,627	$ 	11,402	$ 	13,154	$ 	13,521	$ 	48,704	$ 	10,288	$ 	9,353	$ 	10,929	$ 	10,948	$ 	41,518	$ 	24% 	17%
Costs, Expenses and Other
Cost of sales 	3,199 	3,104 	3,450 	3,873 	13,626 	2,829 	2,747 	3,013 	5,029 	13,618 	-23% 	0%
Selling, general and administrative 	2,187 	2,281 	2,336 	2,830 	9,634 	2,191 	2,085 	2,060 	2,619 	8,955 	8% 	8%
Research and development 	2,412 	4,321 	2,445 	3,068 	12,245 	2,175 	2,085 	3,349 	5,788 	13,397 	-47% 	-9%
Restructuring costs 	297 	82 	107 	174 	661 	70 	82 	113 	310 	575 	-44% 	15%
Other (income) expense, net 	(455) 	(103) 	(450) 	(333) 	(1,341) 	62 	(387) 	(312) 	(253) 	(890) 	32% 	51%
Income (Loss) from Continuing Operations Before Taxes 	2,987 	1,717 	5,266 	3,909 	13,879 	2,961 	2,741 	2,706 	(2,545) 	5,863 	* 	*
Income Tax Provision 	238 	503 	695 	85 	1,521 	495 	396 	380 	69 	1,340
Net Income (Loss) from Continuing Operations 	2,749 	1,214 	4,571 	3,824 	12,358 	2,466 	2,345 	2,326 	(2,614) 	4,523 	* 	*
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	1 	4 	4 	13 	(5) 	4 	2 	3 	4
Net Income (Loss) from Continuing Operations Attributable to
Merck & Co., Inc.
2,745 	1,213 	4,567 	3,820 	12,345 	2,471 	2,341 	2,324 	(2,617) 	4,519 	* 	*
Income (Loss) from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests
434 	332 	- 	(62) 	704 	748 	661 	617 	523 	2,548 	* 	-72%
Net Income (Loss) Attributable to Merck & Co., Inc. 	3,179	$ 	1,545	$ 	4,567	$ 	3,758	$ 	13,049	$ 	3,219	$ 	3,002	$ 	2,941	$ 	(2,094)	$ 	7,067	$ 	* 	85%
Basic Earnings (Loss) per Common Share Attributable to Merck
& Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.08	$ 	0.48	$ 	1.81	$ 	1.51	$ 	4.88	$ 	0.98	$ 	0.93	$ 	0.92	$ 	(1.03)	$ 	1.79	$ 	* 	*
Income (Loss) from Discontinued Operations 	0.17 	0.13 	- 	(0.02) 	0.28 	0.30 	0.26 	0.24 	0.21 	1.01 	* 	-72%
Net Income (Loss) 	1.26	$ 	0.61	$ 	1.81	$ 	1.49	$ 	5.16	$ 	1.27	$ 	1.19	$ 	1.16	$ 	(0.83)	$ 	2.79	$ 	* 	85%
Earnings (Loss) per Common Share Assuming Dilution
Attributable to Merck & Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.08	$ 	0.48	$ 	1.80	$ 	1.51	$ 	4.86	$ 	0.97	$ 	0.92	$ 	0.92	$ 	(1.03)	$ 	1.78	$ 	* 	*
Income (Loss) from Discontinued Operations 	0.17 	0.13 	- 	(0.02) 	0.28 	0.29 	0.26 	0.24 	0.21 	1.00 	* 	-72%
Net Income (Loss) 	1.25	$ 	0.61	$ 	1.80	$ 	1.48	$ 	5.14	$ 	1.26	$ 	1.18	$ 	1.16	$ 	(0.83)	$ 	2.78	$ 	* 	85%
Average Shares Outstanding 	2,531 	2,533 	2,530 	2,527 	2,530 	2,533 	2,527 	2,529 	2,530 	2,530
Average Shares Outstanding Assuming Dilution (1) 	2,541 	2,540 	2,536 	2,535 	2,538 	2,547 	2,536 	2,538 	2,530 	2,541
Tax Rate from Continuing Operations 	8.0% 	29.3% 	13.2% 	2.2% 	11.0% 	16.7% 	14.4% 	14.0% 	-2.7% 	22.9%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
% Change
4Q Full
Year
(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have
been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding.
2021
2Q 	3Q 	4Q 	Full Year	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2020
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2

-- 3 of 10 --

Fourth Quarter
Cost of sales 	3,873	$ 	419 	47 	(4) 	462 	3,411	$
Selling, general and administrative 	2,830 	226 	10 	236 	2,594
Research and development 	3,068 	397 	7 	(17) 	387 	2,681
Restructuring costs 	174 	174 	174 	-
Other (income) expense, net 	(333) 	(3) 	(381) 	(384) 	51
Income From Continuing Operations Before Taxes 	3,909 	(1,039) 	(238) 	381 	21 	(875) 	4,784
Income Tax Provision (Benefit) 	85 	(163) (5) (39) (5) 84 (5) (2) (5) (120) 	205
Net Income from Continuing Operations 	3,824 	(876) 	(199) 	297 	23 	(755) 	4,579
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 3,820 	(876) 	(199) 	297 	23 	(755) 	4,575
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.51	$ 	(0.34) 	(0.08) 	0.12 	0.01 	(0.29) 	1.80	$
Tax Rate 	2.2% 	4.3%
Full Year
Cost of sales 	13,626	$ 	1,607 	160 	221 (3) 1,988 	11,638	$
Selling, general and administrative 	9,634 	322 	19 	341 	9,293
Research and development 	12,245 	479 	28 	1,661 (4) 2,168 	10,077
Restructuring costs 	661 	661 	661 	-
Other (income) expense, net 	(1,341) 	76 	(1,884) 	(1,808) 	467
Income From Continuing Operations Before Taxes 	13,879 	(2,484) 	(868) 	1,884 	(1,882) 	(3,350) 	17,229
Income Tax Provision (Benefit) 	1,521 	(446) (5) (121) (5) 415 (5) (261) (5) (413) 	1,934
Net Income from Continuing Operations 	12,358 	(2,038) 	(747) 	1,469 	(1,621) 	(2,937) 	15,295
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 12,345 	(2,038) 	(747) 	1,469 	(1,621) 	(2,937) 	15,282
Earnings per Common Share Assuming Dilution from
Continuing Operations 4.86	$ 	(0.80) 	(0.30) 	0.58 	(0.64) 	(1.16) 	6.02	$
Tax Rate 	11.0% 	11.2%
Only the line items that are affected by non-GAAP adjustments are shown.
(5) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the full year also includes a $207 million
net tax benefit related to the settlement of certain federal income tax matters.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax
income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs,
including $169 million of transaction costs related to Acceleron. Amounts included in research and development expenses primarily reflect a $275 million in-process research and development (IPR&D) impairment charge
related to the ArQule acquisition, $105 million of Acceleron transaction costs, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the fourth quarter and full year
primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. Additionally,
the full year includes a loss on a forward exchange contract entered into in conjunction with the Organon spin-off.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Reflects charges for the discontinuation of COVID-19 development programs.
(4) Amount includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc. and a $43 million reduction in expense related to measurement period adjustments for the 2020 VelosBio Inc. acquisition.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment Subtotal
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
3

-- 4 of 10 --

Fourth Quarter
Cost of sales 	5,029	$ 	1,986 	44 	260 (5) 2,290 	2,739	$
Selling, general and administrative 	2,619 	42 	10 	52 	2,567
Research and development 	5,788 	16 	16 	3,161 (3) 3,193 	2,595
Restructuring costs 	310 	310 	310 	-
Other (income) expense, net 	(253) 	(2) 	(348) 	(3) 	(353) 	100
(Loss) Income From Continuing Operations Before Taxes 	(2,545) 	(2,042) 	(380) 	348 	(3,418) 	(5,492) 	2,947
Income Tax Provision (Benefit) 	69 	(378) (4) (21) (4) 77 (4) (61) (4) (383) 	452
Net (Loss) Income from Continuing Operations 	(2,614) 	(1,664) 	(359) 	271 	(3,357) 	(5,109) 	2,495
Net (Loss) Income from Continuing Operations
Attributable to Merck & Co., Inc. (2,617) 	(1,664) 	(359) 	271 	(3,357) 	(5,109) 	2,492
(Loss) Earnings per Common Share Assuming
Dilution from Continuing Operations (1.03)	$ 	(0.66) 	(0.14) 	0.11 	(1.32) 	(2.01) 	0.98	$
Tax Rate 	-2.7% 	15.3%
Full Year
Cost of sales 	13,618	$ 	3,355 	175 	260 (5) 3,790 	9,828	$
Selling, general and administrative 	8,955 	225 	47 	272 	8,683
Research and development 	13,397 	12 	83 	4,243 (3) 4,338 	9,059
Restructuring costs 	575 	575 	575 	-
Other (income) expense, net 	(890) 	50 	(1,292) 	(20) 	(1,262) 	372
Income From Continuing Operations Before Taxes 	5,863 	(3,642) 	(880) 	1,292 	(4,483) 	(7,713) 	13,576
Income Tax Provision (Benefit) 	1,340 	(627) (4) (80) (4) 284 (4) (303) (4) (726) 	2,066
Net Income from Continuing Operations 	4,523 	(3,015) 	(800) 	1,008 	(4,180) 	(6,987) 	11,510
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 4,519 	(3,015) 	(800) 	1,008 	(4,180) 	(6,987) 	11,506
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.78	$ 	(1.19) 	(0.31) 	0.40 	(1.65) 	(2.75) 	4.53	$
Tax Rate 	22.9% 	15.2%
Only the line items that are affected by non-GAAP adjustments are shown.
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2020 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
(5) Represents charges for the discontinuation of COVID-19 development programs.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax
income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect a $1.6 billion intangible asset impairment charge related to ZERBAXA and expenses for the amortization of intangible assets. Amounts included in selling, general and
administrative expenses reflect acquisition and divestiture-related costs, including $95 million of transaction costs related to the acquisition of Arqule, Inc. for the full year. Amounts included in other (income) expense, net,
primarily reflect costs related to increases in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint
venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(4) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related costs also includes a tax cost
of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment Subtotal
(3) Amounts for the fourth quarter and full year primarily include charges of $2.7 billion for the acquisition of VelosBio Inc., $462 million for the acquisition of OncoImmune and $45 million for the discontinuation of COVID-19
development programs. Additionally, the full year includes $1.1 billion of charges for upfront payments related to license and collaboration agreements.
4

-- 5 of 10 --

1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $10,627 	$11,402 	$13,154 	$13,521 	$48,704 	$10,288 	$9,353 	$10,929 	$10,948 	$41,518 	24 	23 	17 	16
PHARMACEUTICAL 	9,238 	9,980 	11,496 	12,039 	42,754 	8,905 	8,178 	9,714 	9,813 	36,610 	23 	23 	17 	15
Oncology
Keytruda 	3,899 	4,176 	4,534 	4,577 	17,186 	3,284 	3,388 	3,715 	3,993 	14,380 	15 	16 	20 	18
Alliance Revenue – Lynparza (2) 228 	248 	246 	268 	989 	145 	178 	196 	206 	725 	30 	33 	36 	35
Alliance Revenue – Lenvima (2) 130 	181 	188 	206 	704 	128 	151 	142 	158 	580 	30 	31 	21 	20
Vaccines (3)
Gardasil / Gardasil 9 	917 	1,234 	1,993 	1,528 	5,673 	1,097 	656 	1,187 	998 	3,938 	53 	50 	44 	39
ProQuad / M-M-R II / Varivax 	449 	516 	661 	509 	2,135 	435 	378 	576 	488 	1,878 	4 	4 	14 	13
Pneumovax 23 	171 	152 	277 	292 	893 	256 	117 	375 	339 	1,087 	-14 	-13 	-18 	-19
RotaTeq 	158 	208 	227 	213 	807 	222 	168 	210 	196 	797 	9 	8 	1 	-
Vaqta 	34 	56 	48 	41 	179 	60 	28 	51 	31 	170 	31 	28 	5 	3
Hospital Acute Care
Bridion 	340 	387 	369 	436 	1,532 	299 	224 	320 	355 	1,198 	23 	24 	28 	27
Prevymis 	82 	93 	96 	100 	370 	60 	63 	77 	80 	281 	25 	27 	32 	30
Noxafil 	67 	66 	64 	62 	259 	94 	73 	79 	82 	329 	-25 	-24 	-21 	-23
Primaxin 	65 	60 	70 	65 	259 	51 	64 	74 	62 	251 	5 	2 	3 	-3
Cancidas 	57 	54 	56 	45 	212 	55 	43 	50 	65 	213 	-31 	-32 	- 	-4
Invanz 	57 	48 	53 	45 	202 	64 	43 	51 	53 	211 	-15 	-15 	-4 	-6
Zerbaxa 	(8) 	(1) 	(2) 	10 	(1) 	37 	32 	43 	19 	130 	-47 	-47 	-101 	-101
Immunology
Simponi 	214 	202 	203 	206 	825 	215 	191 	209 	223 	838 	-8 	-6 	-2 	-6
Remicade 	85 	75 	73 	67 	299 	88 	73 	82 	88 	330 	-24 	-22 	-9 	-12
Neuroscience
Belsomra 	79 	78 	81 	80 	318 	79 	84 	81 	83 	327 	-4 	2 	-3 	-1
Virology
Molnupiravir 	952 	952 	* 	* 	* 	*
Isentress / Isentress HD 	209 	192 	189 	178 	769 	245 	196 	205 	211 	857 	-15 	-15 	-10 	-11
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 74 	74 	100 	94 	342 	53 	79 	83 	65 	281 	45 	45 	22 	22
Adempas (5) 55 	74 	59 	63 	252 	56 	57 	55 	53 	220 	19 	24 	14 	11
Diabetes (6)
Januvia 	809 	784 	852 	878 	3,324 	774 	854 	821 	857 	3,306 	3 	3 	1 	-1
Janumet 	486 	477 	487 	514 	1,964 	503 	490 	506 	472 	1,971 	9 	10 	0 	-3
Other Pharmaceutical (7) 581 	546 	572 	610 	2,310 	605 	548 	526 	636 	2,312 	-4 	-4 	0 	-1
ANIMAL HEALTH 	1,418 	1,472 	1,417 	1,261 	5,568 	1,214 	1,101 	1,220 	1,168 	4,703 	8 	8 	18 	16
Livestock 	819 	821 	864 	791 	3,295 	739 	648 	758 	794 	2,939 	- 	- 	12 	10
Companion Animals 	599 	651 	553 	470 	2,273 	475 	453 	462 	374 	1,764 	26 	26 	29 	26
Other Revenues (8) (29) 	(50) 	241 	221 	382 	169 	74 	(5) 	(33) 	205 	* 	* 	86 	176
* 200% or greater
2021 	2020 	4Q 	Full Year
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
(6) Total Diabetes sales were $1,363 million, $1,330 million, $1,417 million, and $1,475 million in the first, second, third, and fourth quarter of 2021, respectively, and $1,353 million, $1,418 million, $1,405
million and $1,412 million in the first, second, third and fourth quarters of 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the first and third quarter of 2021 include $50 million and $135
million, respectively, related to the receipt of milestone payments for an out-licensed product.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $1,809 million, $2,293 million, $3,315 million, and $2,715 million in the first, second, third, and fourth quarter of 2021, respectively, and $2,155 million, $1,418 million, $2,521
million and $2,163 million in the first, second, third and fourth quarters of 2020, respectively.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
5

-- 6 of 10 --

4Q 2021 	4Q 2020 	% Change 	4Q 2021 	4Q 2020 	% Change 	4Q 2021 	4Q 2020 	% Change
TOTAL SALES (1) $13,521 	$10,948 	24 	$6,259 	$5,288 	18 	$7,262 	$5,660 	28
PHARMACEUTICAL 	12,039 	9,813 	23 	5,790 	4,903 	18 	6,249 	4,910 	27
Oncology
Keytruda 	4,577 	3,993 	15 	2,657 	2,246 	18 	1,920 	1,747 	10
Alliance Revenue - Lynparza (2) 268 	206 	30 	144 	120 	20 	123 	85 	44
Alliance Revenue - Lenvima (2) 206 	158 	30 	131 	90 	46 	75 	69 	10
Vaccines (3)
Gardasil / Gardasil 9 	1,528 	998 	53 	275 	546 	-50 	1,253 	452 	177
ProQuad / M-M-R II / Varivax 	509 	488 	4 	374 	345 	8 	135 	144 	-6
Pneumovax 23 	292 	339 	-14 	193 	249 	-22 	99 	90 	10
RotaTeq 	213 	196 	9 	109 	131 	-17 	105 	65 	61
Vaqta 	41 	31 	31 	20 	25 	-19 	21 	7 	*
Hospital Acute Care
Bridion 	436 	355 	23 	218 	172 	27 	218 	183 	19
Prevymis 	100 	80 	25 	42 	32 	30 	58 	48 	21
Noxafil 	62 	82 	-25 	11 	15 	-25 	50 	67 	-25
Primaxin 	65 	62 	5 	1 	* 	64 	62 	4
Cancidas 	45 	65 	-31 	5 	-98 	45 	60 	-25
Invanz 	45 	53 	-15 	(3) 	2 	* 	48 	50 	-5
Zerbaxa 	10 	19 	-47 	9 	17 	-44 	1 	2 	-68
Immunology
Simponi 	206 	223 	-8 	206 	223 	-8
Remicade 	67 	88 	-24 	67 	88 	-24
Neuroscience
Belsomra 	80 	83 	-4 	22 	14 	58 	58 	69 	-16
Virology
Molnupiravir 	952 	* 	632 	* 	320 	*
Isentress / Isentress HD 	178 	211 	-15 	72 	83 	-12 	106 	128 	-17
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 94 	65 	45 	90 	58 	55 	4 	7 	-42
Adempas (5) 63 	53 	19 	0 	- 	63 	53 	19
Diabetes (6)
Januvia 	878 	857 	3 	407 	360 	13 	472 	497 	-5
Janumet 	514 	472 	9 	123 	115 	7 	391 	356 	10
Other Pharmaceutical (7) 610 	636 	-4 	263 	278 	-5 	347 	358 	-3
ANIMAL HEALTH 	1,261 	1,168 	8 	395 	361 	10 	866 	807 	7
Livestock 	791 	794 	158 	165 	-4 	633 	629 	1
Companion Animals 	470 	374 	26 	237 	196 	21 	233 	178 	31
Other Revenues (8) 221 	(33) 	* 	74 	24 	* 	147 	(57) 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(3) Total Vaccines sales were $2,715 million in the fourth quarter of 2021 and $2,163 million in the fourth quarter of 2020.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
FOURTH QUARTER 2021
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,475 million in the fourth quarter of 2021 and $1,412 million in the fourth quarter of 2020.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
6

-- 7 of 10 --

Full Year 2021 Full Year 2020 	% Change 	Full Year 2021 Full Year 2020 	% Change 	Full Year 2021 Full Year 2020 	% Change
TOTAL SALES (1) $48,704 	$41,518 	17 	$22,425 	$19,588 	14 	$26,279 	$21,930 	20
PHARMACEUTICAL 	42,754 	36,610 	17 	20,401 	18,010 	13 	22,353 	18,600 	20
Oncology
Keytruda 	17,186 	14,380 	20 	9,765 	8,352 	17 	7,421 	6,028 	23
Alliance Revenue - Lynparza (2) 989 	725 	36 	515 	417 	24 	473 	308 	54
Alliance Revenue - Lenvima (2) 704 	580 	21 	417 	359 	16 	287 	220 	30
Vaccines (3)
Gardasil / Gardasil 9 	5,673 	3,938 	44 	1,881 	1,755 	7 	3,792 	2,184 	74
ProQuad / M-M-R II / Varivax 	2,135 	1,878 	14 	1,629 	1,378 	18 	506 	500 	1
Pneumovax 23 	893 	1,087 	-18 	547 	727 	-25 	346 	359 	-4
RotaTeq 	807 	797 	1 	473 	486 	-3 	334 	311 	7
Vaqta 	179 	170 	5 	100 	103 	-3 	79 	67 	18
Hospital Acute Care
Bridion 	1,532 	1,198 	28 	762 	583 	31 	770 	615 	25
Prevymis 	370 	281 	32 	153 	119 	28 	218 	162 	35
Noxafil 	259 	329 	-21 	60 	42 	42 	199 	287 	-30
Primaxin 	259 	251 	3 	2 	2 	-36 	258 	248 	4
Cancidas 	212 	213 	4 	7 	-42 	208 	207 	1
Invanz 	202 	211 	-4 	(5) 	9 	-157 	207 	202 	3
Zerbaxa 	(1) 	130 	-101 	4 	74 	-94 	(5) 	56 	-110
Immunology
Simponi 	825 	838 	-2 	825 	838 	-2
Remicade 	299 	330 	-9 	299 	330 	-9
Neuroscience
Belsomra 	318 	327 	-3 	78 	81 	-4 	241 	247 	-2
Virology
Molnupiravir 	952 	* 	632 	* 	320 	*
Isentress / Isentress HD 	769 	857 	-10 	294 	326 	-10 	474 	531 	-11
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 342 	281 	22 	312 	259 	21 	30 	22 	35
Adempas (5) 252 	220 	14 	0 	- 	252 	220 	14
Diabetes (6)
Januvia 	3,324 	3,306 	1 	1,404 	1,470 	-4 	1,920 	1,836 	5
Janumet 	1,964 	1,971 	- 	367 	477 	-23 	1,597 	1,494 	7
Other Pharmaceutical (7) 2,310 	2,312 	- 	1,007 	984 	2 	1,302 	1,328 	-2
ANIMAL HEALTH 	5,568 	4,703 	18 	1,758 	1,484 	18 	3,810 	3,219 	18
Livestock 	3,295 	2,939 	12 	667 	612 	9 	2,628 	2,327 	13
Companion Animals 	2,273 	1,764 	29 	1,091 	872 	25 	1,182 	892 	32
Other Revenues (8) 382 	205 	86 	266 	94 	184 	116 	111 	4
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(3) Total Vaccines sales were $10,132 million and $8,258 million on a global basis for December YTD 2021 and 2020, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
FULL YEAR 2021
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $5,584 million and $5,588 million on a global basis for December YTD 2021 and 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues for
December YTD include $185 million related to the receipt of milestone payments for an out-licensed product.
7

-- 8 of 10 --

TOTAL PHARMACEUTICAL 	$9,238 	$9,980 	$11,496 	$12,039 	$42,754 	$8,905 	$8,178 	$9,714 	$9,813 	$36,610 	23 	17
United States 	4,294 	4,647 	5,670 	5,790 	20,401 	4,308 	3,958 	4,842 	4,903 	18,010 	18 	13
% Pharmaceutical Sales 	46.5% 	46.6% 	49.3% 	48.1% 	47.7% 	48.4% 	48.4% 	49.8% 	50.0% 	49.2%
Europe (1) 2,276 	2,404 	2,445 	2,655 	9,780 	2,116 	1,855 	2,171 	2,314 	8,455 	15 	16
% Pharmaceutical Sales 	24.6% 	24.1% 	21.3% 	22.1% 	22.9% 	23.8% 	22.7% 	22.3% 	23.6% 	23.1%
China 	688 	944 	1,278 	1,352 	4,262 	628 	600 	764 	670 	2,661 	102 	60
% Pharmaceutical Sales 	7.4% 	9.5% 	11.1% 	11.2% 	10.0% 	7.1% 	7.3% 	7.9% 	6.8% 	7.3%
Japan 	607 	637 	614 	771 	2,629 	561 	601 	648 	704 	2,514 	10 	5
% Pharmaceutical Sales 	6.6% 	6.4% 	5.3% 	6.4% 	6.1% 	6.3% 	7.3% 	6.7% 	7.2% 	6.9%
Asia Pacific (other than China and Japan) 	437 	442 	450 	488 	1,817 	411 	377 	411 	414 	1,614 	18 	13
% Pharmaceutical Sales 	4.7% 	4.4% 	3.9% 	4.1% 	4.2% 	4.6% 	4.6% 	4.2% 	4.2% 	4.4%
Latin America 	353 	379 	434 	421 	1,587 	314 	312 	372 	371 	1,369 	13 	16
% Pharmaceutical Sales 	3.8% 	3.8% 	3.8% 	3.5% 	3.7% 	3.5% 	3.8% 	3.8% 	3.8% 	3.7%
Eastern Europe/Middle East/Africa 	357 	318 	362 	278 	1,315 	353 	309 	289 	251 	1,199 	11 	10
% Pharmaceutical Sales 	3.9% 	3.2% 	3.1% 	2.3% 	3.1% 	4.0% 	3.8% 	3.0% 	2.6% 	3.3%
Canada 	160 	157 	164 	167 	650 	159 	121 	169 	149 	599 	12 	9
% Pharmaceutical Sales 	1.7% 	1.6% 	1.4% 	1.4% 	1.5% 	1.8% 	1.5% 	1.7% 	1.5% 	1.6%
Other 	66 	52 	79 	117 	313 	55 	45 	48 	37 	189 	216 	66
% Pharmaceutical Sales 	0.8% 	0.4% 	0.8% 	0.9% 	0.8% 	0.5% 	0.6% 	0.6% 	0.3% 	0.5%
2021 	2020 	% Change
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
Full Year
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
2Q 	3Q 	4Q 	Full Year 	4Q	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
4Q21 	4Q20
Full Year
2021
Full Year
2020
Interest income 	(9)	$ 	(11)	$ 	(36)	$ 	(59)	$
Interest expense 	208 	206 	806 	831
Exchange losses 	95 	56 	297 	145
Income from investments in equity securities, net (1) (403) 	(375) 	(1,940) 	(1,338)
Net periodic defined benefit plan cost (credit) other than service cost 	(53) 	(80) 	(212) 	(339)
Other, net 	(171) 	(49) 	(256) 	(130)
Total 	(333)	$ 	(253)	$ 	(1,341)	$ 	(890)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds
are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --